Please login to the form below

Not currently logged in
Email:
Password:

Daiichi Sankyo buys Plexxikon

The Japanese pharmaceutical company Daiichi Sankyo has agreed to buy the US drug developer Plexxikon in a deal that could be worth $935m

The Japanese pharmaceutical company Daiichi Sankyo has agreed to buy the US drug developer Plexxikon in a deal that could be worth $935m.

The agreement calls for Daiichi Sankyo to make an upfront payment of $805m as well as potential milestone payments of up to $130m tied to the approval of Plexxikon's lead product, a phase III personalised cancer drug known as PLX4032.

"With the acquisition of Plexxikon, we see an opportunity to accelerate the building of our oncology franchise, particularly with the opportunity to co-promote PLX4032," said Daiichi Sankyo, CEO, Joji Nakayama. "Moreover, we have been impressed by the productivity and quality of Plexxikon's pipeline, and discovery and early development capabilities. We intend to provide a high degree of independence to the Plexxikon group to support their continuing success."

PLX4032, an oral, novel kinase inhibitor that targets the oncogenic BRAF mutation, is being co-developed by Plexxikon and Roche under a 2006 agreement. The companies expect to file the therapy this year in the US and Europe as a treatment for metastatic melanoma. They also plan to file a companion diagnostic that they are developing together and intend to launch simultaneously with the therapy.

In January of this year, Plexxikon announced an agreement to co-promote PLX4032 in the US with Roche's US commercial oncology unit, Genentech.

Plexxikon's pipeline also includes drugs in early clinical trials for oncologic indications such as Hodgkin lymphoma, acute myeloid leukaemia, glioblastoma and metastatic breast cancer. In addition, the company has an oral treatment for rheumatoid arthritis in phase I clinical trials.

2nd March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics